Ovoca Bio PLC Appointment of Chief Business Officer (4150B)
09 Outubro 2020 - 3:00AM
UK Regulatory
TIDMOVB
RNS Number : 4150B
Ovoca Bio PLC
09 October 2020
Ovoca Bio plc
("Ovoca" or the "Company")
Ovoca Bio appoints Christopher Wiltshire as Chief Business
Officer
Dublin, Ireland, 9 October, 2020 - Ovoca Bio, a
biopharmaceutical company with a focus on women's health, is
pleased to announce the appointment of Christopher Wiltshire as
Chief Business Officer and Executive Director of the Board,
effective immediately. Mr. Wiltshire previously served as
Non-Executive Director of the Board of Ovoca Bio.
Mr. Wiltshire is an experienced senior pharmaceutical and
biotechnology executive with over 25 years of international
experience. He currently serves as the Chief Executive of
Hematherix LLC which is developing a recombinant clotting factor,
and is former head of Business Development and Licensing at La
Jolla Pharmaceutical (NASDAQ). He has a successful consultancy
practice which provides strategic advice to early and mid-stage
biotechnology and pharmaceutical companies. Mr. Wiltshire
previously served in a number of senior positions at Pfizer,
including as Head of Business Transactions and Investments within
The Pfizer Incubator LLC. Mr. Wiltshire holds an MA in Engineering
from the University of Cambridge and an MBA from the Darden
Graduate School, University of Virginia.
As Chief Business Officer, Mr. Wiltshire will have a key role in
delivering Ovoca Bio's long-term vision of becoming a leader in the
development and commercial partnering of novel medicines in areas
of high unmet need that affect women, in particular through the
ongoing clinical development of BP-101, Ovoca's novel treatment for
premenopausal women suffering from hypoactive sexual desire
disorder (HSDD).
Kirill Golovanov, Chief Executive Officer of Ovoca Bio plc,
said: "Christopher has significant global pharmaceutical industry
experience and has contributed greatly to the strategic direction
of Ovoca Bio as a Non-Executive Director. We are delighted to
welcome him as fulltime CBO and Executive Director. His appointment
comes at an exciting time for the business as we seek to ramp up
clinical development activities for our lead asset, BP-101, in
major global markets."
Christopher Wiltshire said: "Women's health remains an
under-served area with significant unmet medical needs. BP-101 has
great potential as a treatment for women suffering from HSDD and I
look forward to working more closely with the team at Ovoca Bio to
drive its development and ultimate commercialisation
internationally."
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a
focus on women's health. The Company is currently developing a
novel treatment for women with hypoactive sexual desire disorder
(HSDD), a condition characterized by a distressing lack or loss of
sexual desire affecting an estimated 4 million premenopausal women
in the US alone.
The Company's lead product, BP-101, a novel synthetic peptide
administered through a nasal spray, is clinically validated, with
Phase II and Phase III studies conducted in Russia demonstrating
statistically significant improvement in a number of key efficacy
outcomes, including an increase in female sexual desire and
reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global
markets - in particular the United States and Europe, as well as
obtain marketing approval in the Russian Federation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAMRBJTMTAMBJM
(END) Dow Jones Newswires
October 09, 2020 02:00 ET (06:00 GMT)
Ovoca Bio (AQSE:OVB.GB)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Ovoca Bio (AQSE:OVB.GB)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
